Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma

Abstract

The article reviews the key approaches to the use of modified response evaluation criteria in solid tumors (mRECIST) in patients with hepatocellular carcinoma and discusses its main strengths and features. According to the evaluation by mRECIST, complete response is defined as the disappearance of any intratumoral arterial enhancement in all target lesions. A partial response is defined as 30% decrease in the sum of the longest diameters of viable tumor target lesions compared with its baseline sum. Disease progression signifies a ≥20% increase in the sum of the longest diameters of viable tumor target lesions compared with nadir. Stable disease is defined as neither partial response nor progression.